Endocrine Abstracts

Background: Lonapegsomatropin (SKYTROFA™; TransCon hGH), an FDA and EMA approved once-weekly prodrug of somatropin for pediatric growth hormone deficiency (pGHD), uses TransCon® technology to transiently link an inert carrier to a parent drug to achieve sustained release. Daily growth hormone injection, standard treatment for pGHD for decades, may be associated with challenges including needle anxiety and low adherence. The lonapegsomatropin Auto-Injector, winner of ...